MARK KINKEL: Open Payments
NPI 1952185894 · OAKLAND PARK, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,810 in 138 payments from 19 companies in 2025. Trend: 2023 $332 · 2024 $2,524 · 2025 $2,810
Food & beverage: $2,797Education: $12
| Company | Payments | Amount |
|---|---|---|
| ViiV Healthcare Company | 35 | $742 |
| Gilead Sciences, Inc. | 34 | $710 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $275 |
| Novo Nordisk Inc | 15 | $274 |
| Theratechnologies Inc. | 5 | $167 |
| Merck Sharp & Dohme LLC | 6 | $163 |
| EMD Serono, Inc. | 4 | $80 |
| Napo Pharmaceuticals Inc | 3 | $65 |
| Aimmune Therapeutics, Inc. | 2 | $49 |
| Amgen Inc. | 3 | $48 |
Products named: CAPLYTA, RUKOBIA, DOVATO, CABENUVA, EGRIFTA, PIFELTRO, Ozempic, Yeztugo.
Industry payments across FL — which companies pay providers there.
